CANTON, Mass., May 8, 2013 /PRNewswire/ -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the presentation of a scientific poster titled "Oxycodone DETERx®, an Extended-release, Abuse-deterrent Formulation for the Management of Chronic Pain," at the American Pain Society's 32nd Annual Scientific Meeting, held in New Orleans, Louisiana from May 8th to May 10th. This poster summarizes in vitro abuse deterrence study results and the pharmacokinetic profiles for Oxycodone DETERx®, its abuse-deterrent, extended-release opioid.
Poster # 369: Oxycodone DETERx®, an Extended-release, Abuse-deterrent Formulation for the Management of Chronic Pain
Date: Thursday, May 9, 2013 from 9:30am to 11:00am
Presenter: Ernest Kopecky PhD, MBA, VP, Clinical Development and Head Neuroscience TA, Collegium Pharmaceutical, Inc.
About DETERx® Technology
The DETERx® drug delivery platform consists of a multi-particulate matrix formulation in a capsule. While developed primarily to provide abuse-deterrent properties to protect against common methods of tampering such as chewing, crushing, insufflation and extraction for IV injection, the multi-particulate design is expected to enable patients with difficulty swallowing to open the capsule and administer the contents on food or via a gastrostomy tube, while maintaining the extended-release properties of the product. DETERx® technology can be used with drugs that are commonly abused such as opioids and amphetamines, as well as drugs that have narrow therapeutic windows that would benefit from protection against misuse such as breaking, crushing, grinding or dissolving the product. The formulation platform is covered by U.S. and international patents and patent applications. Oxycodone DETERx® is the first of a number of product candidates using the DETERx® platform.
About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx® formulation platform for the treatment of chronic pain. The DETERx® oral drug delivery technology provides extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options. For more information, visit the Company's website at www.collegiumpharma.com.
Michael Heffernan, President
Collegium Pharmaceutical, Inc.
SOURCE Collegium Pharmaceutical, Inc.